Bryostatin 1 structure
|
Common Name | Bryostatin 1 | ||
---|---|---|---|---|
CAS Number | 83314-01-6 | Molecular Weight | 905.033 | |
Density | 1.3±0.1 g/cm3 | Boiling Point | 954.7±65.0 °C at 760 mmHg | |
Molecular Formula | C47H68O17 | Melting Point | N/A | |
MSDS | Chinese USA | Flash Point | 270.0±27.8 °C |
Use of Bryostatin 1Bryostatin 1 is a natural macrolide isolated from the bryozoan Bugula neritina and is a potent and central nervous system (CNS)-permeable PKC modulator. Bryostatin 1 binds to the isolated C1 domain of Munc13-1 and the full-length Munc13-1 protein with Kis of 8.07 nM and 0.45 nM, respectively. Bryostatin 1 has anti-cancer, anti-inflammatory, neuroprotective, anti-HIV-1 infection properties[1][2][3][4]. |
Name | Bryostatin 1,(1S,3S,5Z,7R,8E,11S,12S,13E,15S,17R,21R,23R,25S)-25-(Acetyloxy)-1,11,21-trihydroxy-17-[(1R)-1-hydroxyethyl]-5,13-bis(2-methoxy-2-oxoethylidene)-10,10,26,26-tetramethyl-19-oxo-18,27,28,29-tetraoxatetracyclo[21.3.1.13,7.111,15]nonacos-8-en-12-y |
---|---|
Synonym | More Synonyms |
Description | Bryostatin 1 is a natural macrolide isolated from the bryozoan Bugula neritina and is a potent and central nervous system (CNS)-permeable PKC modulator. Bryostatin 1 binds to the isolated C1 domain of Munc13-1 and the full-length Munc13-1 protein with Kis of 8.07 nM and 0.45 nM, respectively. Bryostatin 1 has anti-cancer, anti-inflammatory, neuroprotective, anti-HIV-1 infection properties[1][2][3][4]. |
---|---|
Related Catalog | |
Target |
PKC[1] HIV-1[4] |
In Vitro | Bryostatin 1 (1 µM; 5 minutes; HT22 cells) treatment successfully recruits Munc13-1 from the cytosol to the plasma membrane. Effects of Bryostatin 1 on the other Munc13 family members, ubMunc13-2 and bMunc13-2, resembled those of Munc13-1 for translocation [1]. The increased level of expression of Munc13-1 following a 24 h incubation with Bryostatin 1 in both HT22 and primary mouse hippocampal cells is observed[1]. Bryostatin 1 can also affect the immune system by modulating dendritic cells (DCs) via toll-like receptor 4 (TLR4) through the MyD88-independent pathway, which favors an anti-inflammatory environment by inducing a type 2 phenotype that promotes the differentiation of CD4+ T-helper (Th) lymphocytes into Th2 versus Th1 effector cells[2]. Western Blot Analysis[1] Cell Line: HT22 cells Concentration: 1 µM Incubation Time: 5 minutes Result: Caused Munc13-1 to transfer to the membrane fraction. |
In Vivo | Bryostatin 1 (30 μg/kg; intraperitoneal injection; 3 d per week; for 2 weeks; C57BL/6J mice) treatment abolishes the onset of EAE[2]. Animal Model: Female C57BL/6J mice (8-12-week-old) with MOG35-55[2] Dosage: 30 μg/kg Administration: Intraperitoneal injection; 3 d per week; for 2 weeks Result: Abolished the onset of experimental autoimmune encephalomyelitis (EAE). |
References |
Density | 1.3±0.1 g/cm3 |
---|---|
Boiling Point | 954.7±65.0 °C at 760 mmHg |
Molecular Formula | C47H68O17 |
Molecular Weight | 905.033 |
Flash Point | 270.0±27.8 °C |
Exact Mass | 904.445679 |
PSA | 240.11000 |
LogP | 5.39 |
Vapour Pressure | 0.0±0.6 mmHg at 25°C |
Index of Refraction | 1.565 |
CHEMICAL IDENTIFICATION
HEALTH HAZARD DATAACUTE TOXICITY DATAMUTATION DATA
|
Personal Protective Equipment | Eyeshields;Gloves;type N95 (US);type P1 (EN143) respirator filter |
---|---|
Safety Phrases | S22-S24/25 |
RIDADR | NONH for all modes of transport |
RTECS | EH9455000 |
Bryostatin-1 promotes long-term potentiation via activation of PKCα and PKCε in the hippocampus.
Neuroscience 226 , 348-55, (2012) Activation of protein kinase C (PKC) by bryostatin-1 affects various functions of the central nervous system. We explored whether bryostatin-1 influenced synaptic plasticity via a process involving PK... |
|
Bryostatin-I: A dendritic cell stimulator for chemokines induction and a promising adjuvant for a peptide based cancer vaccine
Cytokine 52(3) , 238-44, (2010) Bryostatin-1 (Bryo-1), a PKC modulator, was previously shown to activate monocytes and lymphocytes to produce cytokines. In this report, we investigated the adjuvanticity of Bryo-1 both in vitro and i... |
|
Differentiation therapy in poor risk myeloid malignancies: Results of a dose finding study of the combination bryostatin-1 and GM-CSF.
Leuk. Res. 35(1) , 87-94, (2011) Pharmacologic differentiating agents have had relatively limited clinical success outside of the use of ATRA in acute promyelocytic leukemia and DNA methyltransferase inhibitors in myelodysplastic syn... |
2,4-Octadienoic acid, (1S,3S,5Z,7R,8E,11S,12S,13E,15S,17R,21R,23R,25S)-25-(acetyloxy)-1,11,21-trihydroxy-17-[(1R)-1-hydroxyethyl]-5,13-bis(2-methoxy-2-oxoethylidene)-10,10,26,26-tetramethyl-19-oxo-18, ;27,28,29-tetraoxatetracyclo[21.3.1.1.1]nonacos-8-en-12-yl ester, (2E,4E)- |
(1S,3S,5Z,7R,8E,11S,12S,13E,15S,17R,21R,23R,25S)-25-Acetoxy-1,11,21-trihydroxy-17-[(1R)-1-hydroxyethyl]-5,13-bis(2-methoxy-2-oxoethylidene)-10,10,26,26-tetramethyl-19-oxo-18,27,28,29-tetraoxatetracyclo[21.3.1.1.1]nonacos-8-en-12-yl (2E,4E)-2,4-octadienoate |
2,4-octadienoic acid, (1S,3S,5Z,7R,8E,11S,12S,13E,15S,17R,21R,23R,25S)-25-(acetyloxy)-1,11,21-trihydroxy-17-[(1R)-1-hydroxyethyl]-5,13-bis(2-methoxy-2-oxoethylidene)-10,10,26,26-tetramethyl-19-oxo-18,27,28,29-tetraoxatetracyclo[21.3.1.1.1]nonacos-8-en-12-yl ester, (2E,4E)- |
MFCD00893832 |
bryostatin1,0 |
(1S,3S,5Z,7R,8E,11S,12S,13E,15S,17R,21R,23R,25S)-25-Acetoxy-1,11,21-trihydroxy-17-[(1R)-1-hydroxyethyl]-5,13-bis(2-methoxy-2-oxoethylidene)-10,10,26,26-tetramethyl-19-oxo-18,27,28,29-tetraoxatetracycl ;o[21.3.1.1.1]nonacos-8-en-12-yl (2E,4E)-2,4-octadienoate |
(1S,3S,5Z,7R,8E,11S,12S,13E,15S,17R,21R,23R,25S)-25-(acetyloxy)-1,11,21-trihydroxy-17-[(1R)-1-hydroxyethyl]-5,13-bis(2-methoxy-2-oxoethylidene)-10,10,26,26-tetramethyl-19-oxo-18,27,28,29-tetraoxatetracyclo[21.3.1.1.1]nonacos-8-en-12-yl (2E,4E)-octa-2,4-dienoate |
BRYO 1 |
bryostatine-1 |
BRYOSTATIN 1 |
BRYOSTATIN |